UBS Group
KPTI icon

UBS Group’s Karyopharm Therapeutics KPTI Stock Holding History

UBS Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
194,017
+105,562
+119% +$805K ﹤0.01% 5498
2025
Q4 		$651K Buy
88,455
+28,770
+48% +$176K ﹤0.01% 5914
2025
Q3 		$390K Sell
59,685
-102,215
-63% -$550K ﹤0.01% 6263
2025
Q2 		$698K Buy
161,900
+68,288
+73% +$335K ﹤0.01% 5741
2025
Q1 		$350K Buy
93,612
+83,893
+863% +$716K ﹤0.01% 6125
2024
Q4 		$98.6K Buy
9,719
+754
+8% +$9.12K ﹤0.01% 6885
2024
Q3 		$112K Sell
8,965
-414
-4% -$5.14K ﹤0.01% 6273
2024
Q2 		$122K Sell
9,379
-7,617
-45% -$126K ﹤0.01% 6036
2024
Q1 		$385K Sell
16,996
-13,483
-44% -$236K ﹤0.01% 5389
2023
Q4 		$395K Sell
30,479
-29,964
-50% -$404K ﹤0.01% 5291
2023
Q3 		$1.21M Buy
60,443
+31,269
+107% +$702K ﹤0.01% 3906
2023
Q2 		$783K Buy
29,174
+18,345
+169% +$790K ﹤0.01% 4452
2023
Q1 		$632K Sell
10,829
-24,055
-69% -$1.19M ﹤0.01% 4510
2022
Q4 		$1.78M Buy
34,884
+27,381
+365% +$1.9M ﹤0.01% 3509
2022
Q3 		$614K Sell
7,503
-13,666
-65% -$1.02M ﹤0.01% 4159
2022
Q2 		$1.43M Sell
21,169
-13,395
-39% -$1.23M ﹤0.01% 3415
2022
Q1 		$3.82M Buy
34,564
+16,764
+94% +$2.09M ﹤0.01% 2801
2021
Q4 		$1.72M Sell
17,800
-22,766
-56% -$2.27M ﹤0.01% 3874
2021
Q3 		$3.54M Buy
40,566
+20,997
+107% +$2.18M ﹤0.01% 3043
2021
Q2 		$3.03M Buy
19,569
+9,834
+101% +$1.43M ﹤0.01% 3176
2021
Q1 		$1.54M Buy
9,735
+5,149
+112% +$1.08M ﹤0.01% 3826
2020
Q4 		$1.06M Sell
4,586
-8,989
-66% -$2.08M ﹤0.01% 3966
2020
Q3 		$2.97M Buy
13,575
+4,620
+52% +$1.13M ﹤0.01% 2686
2020
Q2 		$2.54M Buy
8,955
+8,467
+1,735% +$2.5M ﹤0.01% 2654
2020
Q1 		$141K Sell
488
-534
-52% -$147K ﹤0.01% 4993
2019
Q4 		$294K Sell
1,022
-12,561
-92% -$2.73M ﹤0.01% 5312
2019
Q3 		$1.96M Buy
13,583
+13,402
+7,404% +$1.82M ﹤0.01% 3301
2019
Q2 		$16K Hold
181
– – ﹤0.01% 6766
2019
Q1 		$16K Sell
181
-14,269
-99% -$1.58M ﹤0.01% 6488
2018
Q4 		$2.03M Buy
14,450
+13,497
+1,416% +$2.28M ﹤0.01% 3025
2018
Q3 		$243K Buy
953
+315
+49% +$87.1K ﹤0.01% 4917
2018
Q2 		$163K Sell
638
-671
-51% -$166K ﹤0.01% 5100
2018
Q1 		$264K Buy
1,309
+1,157
+761% +$231K ﹤0.01% 4601
2017
Q4 		$21K Sell
152
-738
-83% -$119K ﹤0.01% 6514
2017
Q3 		$147K Buy
890
+645
+263% +$92.4K ﹤0.01% 5061
2017
Q2 		$33K Buy
245
+152
+163% +$22.5K ﹤0.01% 5954
2017
Q1 		$18K Sell
93
-64
-41% -$10.3K ﹤0.01% 6207
2016
Q4 		$22K Sell
157
-16
-9% -$2.16K ﹤0.01% 6456
2016
Q3 		$26K Buy
173
+53
+44% +$6.37K ﹤0.01% 6066
2016
Q2 		$12K Sell
120
-4
-3% -$520 ﹤0.01% 6678
2016
Q1 		$17K Sell
124
-220
-64% -$24.3K ﹤0.01% 6321
2015
Q4 		$68K Buy
344
+313
+1,010% +$67.8K ﹤0.01% 5556
2015
Q3 		$5K Sell
31
-74
-70% -$19.8K ﹤0.01% 7708
2015
Q2 		$43K Sell
105
-5,778
-98% -$2.5M ﹤0.01% 6124
2015
Q1 		$2.7M Sell
5,883
-6,500
-52% -$2.8M ﹤0.01% 2650
2014
Q4 		$6.95M Buy
+12,383
New +$7.03M ﹤0.01% 1805

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

UBS Group's KPTI Position: Q1 2026 in Review

UBS Group increased its Karyopharm Therapeutics (KPTI) stake by 119% in Q1 2026, buying an estimated $805K and bringing the position to 194,017 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5498.

UBS Group first reported a position in KPTI in Q4 2014 and has held it in 46 quarters since. The position peaked at $6.95M in Q4 2014. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • UBS Group held 194,017 shares of Karyopharm Therapeutics worth $1.08M as of Q1 2026.
  • UBS Group bought 105,562 Karyopharm Therapeutics shares in Q1 2026, an estimated $805K.
  • Karyopharm Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5498 holding.
  • UBS Group first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Karyopharm Therapeutics position peaked at $6.95M in Q4 2014.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.